Use of iPSC derived brain cells to model neurodegenerative disorders

Commonly used acronym: iPSC-brain

Scope of the method

Alternative method relates to
  • Human health
Alternative method is situated in
  • Basic Research
  • Translational - Applied Research
Type of alternative method
  • In vitro - Ex vivo
This method makes use of
  • Animal derived cells / tissues / organs
Species from which cells/tissues/organs are derived
human
Type of cells/tissues/organs
brain

Description

Method keywords
  • IPSC
  • 2D models
  • 3D models being created
  • neural and glial cells
  • CRISPR/Cas
Scientific area keywords
  • AD
  • FTD
  • ALS
  • MS
Method description

Despite major advances in our understanding of neurodegenerative disorders, no efficient therapies are available for patients with dementia, motor neuron disease and other neurodegenerative disorders. With the advent of pluripotent stem cells (PSCs) it now becomes possible to better model human disease in vitro (and in humanized mice), which may lead to the development of novel therapies for these currently untreatable disorders. We are building such models, using PSC-derived cells combined with genome engineering to study neuronal characteristics but also glial (astrocyte, oligodendrocyte and microglia) contribution to neurodegeneration in 2D (downscaled to medium/high throughput 384 well plate formats for medium/high throughput screening and high content imaging) and starting to develop 3D models, to identify novel therapeutic targets and therapies.

Lab equipment
  • Laminar flow 
  • Incubator,
  • Microfluidics device 
  • qRT-PCR
  • Automated robotised stem cell platform
  • High content imager
Method status
  • Still in development
  • Internally validated

References, associated documents and other information

Associated documents

Organisations

KU Leuven
Development and Regeneration
Belgium